TNXP - Tonix Pharmaceuticals Holding Corp.
| Previous Close | 1.6700 |
| Open | 1.6800 |
| Bid | 0.0000 x 1100 |
| Ask | 2.2600 x 800 |
| Day's Range | 1.6032 - 1.7000 |
| 52 Week Range | 0.3600 - 9.6000 |
| Volume | 108,851 |
| Avg. Volume | 1,544,390 |
| Market Cap | 9.987M |
| Beta (3Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.5910 |
| Earnings Date | Aug 12, 2019 - Aug 16, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.83 |
- GlobeNewswire•3 days ago
Tonix Pharmaceuticals Announces Director Stepping Down
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) announced that Donald W. Landry, M.D., Ph.D., is stepping down from the Company’s Board of Directors, effective May 16, 2019. Dr. Landry has served on the Board of Directors of Tonix since 2011 and co-founded Tonix Pharmaceuticals in 2007, along with Seth Lederman, M.D., Chief Executive Officer of Tonix. “Tonix Pharmaceuticals was founded with the vision of discovering and developing pharmaceutical products to treat serious psychiatric and pain conditions,” said Dr. Landry.
- GlobeNewswire•7 days ago
Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense, today announced financial results for the quarter ended March 31, 2019 and an overview of recent operational highlights. Tonix’s lead program is TNX-102 SL, or Tonmya* (cyclobenzaprine HCl sublingual tablets), for the treatment of posttraumatic stress disorder (PTSD), which was granted Breakthrough Therapy designation and which is currently being studied in a Phase 3 efficacy trial. The FDA also advised that the long-term safety exposure data from the Company’s PTSD program may be used to support a New Drug Application (NDA) for the treatment of fibromyalgia. It is estimated that between 5-10 million adults in the U.S. are affected by fibromyalgia, of which approximately 3 million are diagnosed.
- GlobeNewswire•12 days ago
Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors, effective May 6, 2019. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “We are pleased to welcome Dr. Goodman to the Tonix Board, as he brings 20 years of biopharmaceutical research and development leadership experience that will be invaluable to Tonix as we grow the company.
- GlobeNewswire•27 days ago
Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), announced on April 18, 2019 that the Company received a notice of termination, effective April 29, 2019, whereby USAMMDA is exercising its contractual right to terminate without cause the CRADA entered into on December 4, 2015 between the Company and USAMMDA relating to the development of Tonmya* or TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of Posttraumatic Stress Disorder (PTSD). The termination does not affect Tonix’s finances or the conduct of the ongoing RECOVERY trial in PTSD.
- GlobeNewswire•28 days ago
Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder
NEW YORK, April 22, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical.
- MarketWatch•last month
Tonix Pharmaceuticals R&D pact with U.S. Army to be terminated 'without cause'
Tonix Pharmaceuticals Holding Corp. disclosed Friday that the U.S. Army Medical Material Development Activity (USAMMDA) is exercising its right to "terminate without cause" the research and development agreement with the company. The termination of the agreement, which Tonix and USAMMDA entered in December 2015, is effective April 29. Tonix has two development programs focused on post-traumatic stress disorder (PTSD), and is currently enrolling participants in a phase 3 trial. The stock has gained 8.2% year to date, but has plunged 93% over the past 12 months, while the S&P 500 has gained 16% year to date and advanced 7.9% the past year.
- Zacks Small Cap Research•last month
TNXP: Phase 3 Trial of TNX-102 SL in PTSD Underway…
On March 11, 2019, Tonix Pharmaceuticals Holding Corp. (TNXP) announced the first patient has been enrolled in the RECOVERY Phase 3 study of TNX-102 SL in patients with posttraumatic stress disorder (PTSD). The RECOVERY trial is a randomized, double blind, placebo controlled study of TNX-102 SL over 12 weeks with the primary endpoint being the Week 4 change in CAPS-5 score from baseline between TNX-102 SL and placebo-treated patients. 1) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR trial included individuals who experienced a trauma from 2001 or later.
- ACCESSWIRE•2 months ago
Four Healthcare Stocks Heating Up on Thursday
This predicted growth is an indicator that more people will soon need access to quality medical care and the healthcare sector must be aptly prepared. As the healthcare sector continues to progress into the future, investors interested in potentially lucrative opportunities could benefit from focusing on this sector. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Shineco Inc (TYHT), Tonix Pharmaceuticals Holding Corp (TNXP), and Sunesis Pharmaceuticals Inc (SNSS) are 4 healthcare companies worth keeping on your radar.
- Benzinga•2 months ago
What's Driving The Rally In Nanocap Biotech Tonix Pharma?
Tonix, a biopharma company developing treatments for serious neuropsychiatric and central nervous system conditions, said it plans to expand its TNX-102 SL 5.6 mg program beyond post-traumatic stress disorder. TNX-102 SL, or Tonmya, a non-opioid, centrally acting analgesic, is the company's lead late-stage asset being evaluated for PTSD in a Phase 3 trial. The trial, dubbed RECOVERY, is actively enrolling military and civilian PTSD participants.
- GlobeNewswire•2 months ago
Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric and central nervous system conditions, and biological products to improve biodefense, announced today the expansion of the TNX-102 SL 5.6 mg program beyond posttraumatic stress disorder (PTSD) to include Phase 3 development for TNX-102 SL* in fibromyalgia.
- GlobeNewswire•2 months ago
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences
NEW YORK, March 25, 2019 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at two upcoming.
- GlobeNewswire•2 months ago
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix, or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, today announced financial results for the fourth quarter and full year ended December 31, 2018, and an overview of recent operational highlights. “Looking forward into 2019, we are excited about the recent initiation of our new Phase 3 study of Tonmya for PTSD.
- GlobeNewswire•2 months ago
Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences
Investors interested in arranging a meeting with the Company’s management during either conference should contact the respective conference coordinator. Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures.
- ACCESSWIRE•2 months ago
Four Healthcare Stocks Making Moves on Monday
CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The future of the healthcare stock market, and the medical sector in its entirety, is largely dependent on whether medical experts and healthcare professionals are aptly prepared to meet the growing demands of patients. As companies in the healthcare sector work to develop innovative technologies for their patients, these efforts may create potential opportunities for investors looking to the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Axovant Sciences Ltd (AXGT), Tonix Pharmaceuticals Holding Corp (TNXP), and Cellect Biotechnology Ltd (APOP) are 4 healthcare companies looking to kick off a strong week of trading.
- GlobeNewswire•2 months ago
Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today that the first participant was enrolled in the RECOVERY study, a new Phase 3 study of Tonmya* (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of posttraumatic stress disorder (PTSD). “Tonix is committed to improving the lives of the millions who suffer from PTSD, especially military-related PTSD, and enrolling the first participant in the RECOVERY study is an important step towards achieving this goal,” said Seth Lederman, M.D., Tonix's President and Chief Executive Officer.
- ACCESSWIRE•2 months ago
Four Healthcare Stocks Surpassing Investor Expectations
CORAL GABLES, FL / ACCESSWIRE / March 8, 2019 / When it comes to discussing healthcare stock market, it goes without saying that the success of the market is directly connected to if companies in the healthcare industry are doing their part to take care of consumers. It is the responsibility of healthcare companies to work to develop innovative treatments and care options for consumers, especially at a time where new diseases are discovered on a frequent basis. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Tonix Pharmaceuticals Holding Corp (TNXP), Steller Biotechnologies Inc (SBOT), NantHealth Inc (NH) are 4 healthcare companies stepping up their game on Friday.
- GlobeNewswire•2 months ago
Tonix Pharmaceuticals Announces New European Use Patent for TNX-601
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, today announced that the European Patent Office (EPO) issued European Patent No. 3246031 to the Company on February 27, 2019. The patent, “Method for Treating Neurodegenerative Dysfunction,” claims the use of TNX-601, or tianeptine oxalate and other salts, for treating neurocognitive dysfunction associated with corticosteroid treatment.
- GlobeNewswire•3 months ago
Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, today announced program updates related to the development of Tonmya* (cyclobenzaprine HCl sublingual tablets) which is in Phase 3 development for the treatment of posttraumatic stress disorder (PTSD). The U.S. Food and Drug Administration (FDA) notified the Company that the Breakthrough Therapy designation (BTD) granted for Tonmya for PTSD in December 2016 has been rescinded because interim analysis data on Tonmya from the HONOR study do not support the continuation of the BTD. The BTD granted to Tonmya was based on retrospective analysis of the effect of Tonmya 5.6 mg in the Phase 2 AtEase study in military-related PTSD, that shows a substantial improvement over existing therapies in military-related PTSD.
- GlobeNewswire•3 months ago
Tonix Pharmaceuticals Announces Share Repurchase Program
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) today announced that its Board of Directors has approved a share repurchase program pursuant to which the Company may repurchase up to $2 million in value of its outstanding common stock, par value, $0.001 per share, from time to time on the open market and in privately negotiated transactions subject to market conditions, share price and other factors (the “Share Repurchase Program”). The Company intends to fund the Share Repurchase Program with available cash. The timing and amount of any shares repurchased will be determined based on the Company’s evaluation of market conditions and other factors and the program may be discontinued or suspended at any time.
- GlobeNewswire•3 months ago
Tonix Pharmaceuticals Announces New Board Member, James Treco
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) today announced the appointment of James Treco to its Board of Directors, effective immediately. Mr. Treco assumes the seat held by Charles Mather, who has stepped down from the position of company director that he has held since 2011. Seth Lederman, M.D., President and Chief Executive Officer of Tonix commented, “We are pleased to welcome Mr. Treco to the Tonix Board.
- Simply Wall St.•3 months ago
How Many Insiders Bought Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companies Read More...
- GlobeNewswire•3 months ago
Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at the 21st Annual BIO CEO & Investor Conference on February 11, 2019. A live webcast and subsequent archived recording of the Company presentations will be available under the IR Events tab of the Investor Relations section of the Tonix Pharmaceuticals website at www.tonixpharma.com.
- Zacks Small Cap Research•5 months ago
TNXP: Additional Details Revealed for Phase 3 Trial of TNX-102 SL in PTSD Starting in 1Q19…
2) Inclusion will be limited to individuals with PTSD who experienced their trauma within the past nine years, while the HONOR trial included individuals who experienced a trauma from 2001 or later. 3) The study will include both civilian and military PTSD patients, while the HONOR trial had limited inclusion to only those with military-related PTSD.
- GlobeNewswire•5 months ago
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences in January 2019.
- GlobeNewswire•5 months ago
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced that it has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Global Market. On November 28, 2018, Tonix effected a 1-for-10 reverse stock split of its outstanding common stock intended to increase the per share trading price of Tonix’s common stock to satisfy the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Global Market, as set forth in NASDAQ Listing Rule 5450(a)(1) (the “Bid Price Rule”).
